I was commenting in general on his investment targets, and while I have a small position in THLD and hope they are able to survive and realize the potential value from their pipeline, it is longshot. As you indicated, there is a "possible" partnership for Glufo, but the clinical results cannot be considered "robust" and if some company is interested in pursuing the hypoxia angle, why would they invest in Glufo, when TH-302 appears to have much more potential (based on the pre-clinical data). In other words, I believe there is value in the pipeline, but the company doesn't have enough cash to realize that value in the clinic and they don't have the leverage to negotiate a valuable (i.e. substantial up-front money)partnership on Glufo, so the most likely scenario is a buyout. The question is whether they can generate any meaningful clincal data on TH-302 before they put the company on the block?